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1. INTRODUCTION
Tuberculosis still remains a major public health problem despite the fact that the causative organism 
was discovered some 100 years back and highly effective drugs are available for its treatment.
Worldwide 9.1 million cases are detected annually out of which half  are sputum positive .1 
South  East  Asia  which  account  for  25% of  the  world’s  population  accounts  for  34% of  world’s 
tuberculosis burden .1
WHO has identified 22 high burden countries in terms of tuberculosis incidence which account 
for 80% of global tuberculosis burden.1
India ranks 17th among 22 high burden countries in terms of tuberculosis incidence rate.1 India is 
the country with the highest burden of tuberculosis in the world accounting for 1/8 th of the global 
incidence of tuberculosis.2 Annually, around 1.9 million cases of tuberculosis are detected in India out 
of which 0.8 million are sputum positive infectious cases.2  
In India, everyday more than 5000 people develop tuberculosis disease and nearly 1000 die due 
to tuberculosis i.e. 2 deaths every 3 minutes.2 Deaths due to tuberculosis exceed the combined deaths 
due to all other communicable diseases and account for 26% of all avoidable deaths in adults.2
Tuberculosis affects the most productive age group. Of all tuberculosis cases in India 2/3rd are 
male and 70% of all patients are aged between 15 and 54 years.3 More than 3,00,000 children are 
forced  to  leave  school  because  their  parents  have  tuberculosis  and  about  1,00,000  women  with 
tuberculosis are rejected by their families annually.3
Direct and indirect cost of tuberculosis to India for morbidity alone amounts to an estimated $ 3 
billion annually (2000).3 Studies suggested on an average 3 to 4 months of work time  is lost as a result 
of tuberculosis, resulting in an average potential loss of 20-30% of the annual household income.3
There  is  an  increasing  concern  about  drug  resistant  tuberculosis.  Several  small  surveys 
conducted across the country have shown the prevalence rates of Multi Drug Resistant Tuberculosis 
(strains  of  Mycobacterium tuberculosis  resistant  to  both  Isoniazid  and  Rifampicin)  of  around  3% 
among new cases and 12% among retreatment cases.4, 5 
With increase in incidence of HIV infection , there is increasing focus on HIV-TB co-infection. 
An HIV infected person co-infected  with tubercle  bacilli  has  50-60% life  time risk of  developing 
tuberculosis disease as compared to a 10% life time risk of developing tuberculosis disease in a non-
HIV infected person.6  Tuberculosis infection refers to a positive tuberculin skin test with or without 
signs and symptoms of disease. Tuberculosis disease refers to cases who have positive acid-fast smear 
culture  from Mycobacterium tuberculosis  or  radiographic  and clinical  presentation  of  tuberculosis. 
Investigation of people exposed to cases of infectious tuberculosis (contact investigation) is the key to 
tuberculosis control in countries with low tuberculosis incidence. However, in countries in which the 
incidence of tuberculosis is high (like India); contact investigation is not commonly done. 
2. JUSTIFICATION
The status of the disease and disease trends is one of the basic requirements in the development 
of control programme for that disease and its subsequent evaluation. Subjects in contact with infective 
pulmonary tuberculosis may be infected if the index case coughs and expels Mycobacteria into the air. 
Infected contacts will then develop a progressive immune response and some (between 5-10% of those 
who  are  exposed)  will  develop  tuberculosis  disease  within  their  lifespan.  This  progression  from 
infection to  disease will  depend on several  factors  ,  such as  age,  sex,  size  of  tuberculin reaction, 
immune status, diabetes, smoking, drug treatment and nutritional status.7,8,9,10 The risk of developing 
tuberculosis disease from tuberculosis infection is maximum in the first 2 years following infection and 
decreases with time.11
In  all  countries  the  first  priority is  rapid  detection  of  cases  and their  prompt  treatment.  In 
regions  with  a  high  incidence  of  tuberculosis  a  search  for  contacts  among  the  relatives  of  smear 
positive cases may succeed in detecting large number of secondary cases, but the search for infected 
contacts is less of a priority except among close relatives and small children, who may rapidly develop 
severe forms of the disease.12
Soon  after  the  introduction  of  antibiotics  (as  early  as  1959),  trials  were  conducted  which 
demonstrated that, if properly prescribed and taken, preventive treatment reduces the risk of future 
disease and is cost-effective.13, 14
In theory at least, if applied rigorously to infected individuals or to whole population with a 
high rate of latent tuberculosis infection, this policy could be successful in lowering the incidence of 
tuberculosis in future.16 
As individuals with latent infection with tuberculosis by definition are healthy and do not have 
radiological abnormalities (except in few cases), screening must rely on immunological markers of 
infection. For nearly a century the screening for latent tuberculosis infection relied on Tuberculin Skin 
Testing (TST). While TST is a useful guide for identifying tuberculosis infection, it has a number of 
drawbacks including the need for a repeat visit to read the test, problems in interpretation due to cross-
reactivity with other mycobacterial species, the booster effect, and false negative results because of 
intercurrent immunosupression, as well as the variability inherent in its application and reading.17The 
recent  introduction  of  T-cell  based  interferon  gamma  assay  (IFN-γ )  has  demonstrated  a  role  in 
screening  for  Mycobacterium tuberculosis  infection,  contact  tracing,  and  has  reportedly  overcome 
some of the drawbacks of TST.18,19,20,21
Most  of  these  studies  demonstrating  the  efficacy  of  interferon  gamma  assay  are  in  low 
incidence countries. More studies are needed for finding the prevalence of latent tuberculosis infection 
in high prevalence countries using TST and the new IGRA test.
The present study will serve two purposes. Firstly, it will help in contributing to the present 
knowledge about the prevalence of latent tuberculosis infection among household contacts of infective 
tuberculosis cases. Secondly, this study will also measure the agreement between TST and IGRA tests 
in diagnosing  latent tuberculosis infection in household contacts of infective tuberculosis cases. 
3. OBJECTIVES
1. To estimate the prevalence of latent tuberculosis infection in the  household contacts of sputum 
culture positive tuberculosis patients among suspected multi drug resistant tuberculosis patients 
in a population covered by CHAD Tuberculosis Unit and District Tuberculosis Centre  TB Unit 
in Vellore district using tuberculin skin testing (TST) and whole blood interferon gamma (i.e. 
Quantiferon TB –Gold).
2. To find the agreement between Quantiferon TB-Gold and TST in detecting latent tuberculosis 
infection in the above population.
4. LITERATURE   REVIEW
4.1 Magnitude of the Problem
Tuberculosis  represents  a  serious  public  health  issue  worldwide.  The  2008   World  Health 
Organization Report  on tuberculosis  states that  a total  of 9.2 million new cases (139 per 1,00,000 
population)  and 1.7 million deaths  from tuberculosis  occurred  worldwide  in  2006.1 Deaths  due to 
tuberculosis comprises 25% of all avoidable deaths in developing countries.1  In developing countries 
75% of all tuberculosis cases die in the productive age group of 15 – 50 years. 1
The largest number of cases occur in South East Asia which accounts for 34% of all incident 
cases globally.1 In 2007 there were an estimated 5.7 million cases in this region. Every year, 3 million 
people develop active tuberculosis in this region and 50,000 die.1  In South East Asia 80% of all cases 
are in the age group of 15-54 years.1  Bangladesh, India, Indonesia, Myanmar and Thailand accounted 
for 95% of global tuberculosis burden.1
Tuberculosis is the biggest public health problem in India. With 1.8 million new cases occurring 
annually, India accounts for a fifth of the world’s new cases and 2/3rd of all the new cases in South East 
Asia.2 More than 80% of the burden of tuberculosis is due to premature deaths, as measured  in terms of 
Disability  Adjusted  Life  Years  (DALY)  lost.2Among  all  cases  70%  occur  in  the  economically 
productive age group of 15-54 years.2  Tuberculosis causes huge economic loss with about 17 crores 
workdays lost due to the disease every year.3  
It  is  estimated  that  between 2002 and 2020,  approximately 1 billion  people  will  be newly 
infected, over 150 million will get sick and 36 million will die of tuberculosis, if control measures are 
not strengthened.3 
4.2 Diagnosing Latent Tuberculosis Infection
Latent  tuberculosis  infection  is  a  sub  clinical  infection  with  Mycobacterium  tuberculosis 
without clinical, bacteriological, or radiological evidence of tuberculosis disease. The standard test for 
diagnosis of latent tuberculosis infection is TST.
4.2.1 Standard Tuberculin Test
4.2.1.1 Tuberculin
The  tuberculin  skin  test  has  been  the  standard  method  of  diagnosing  infection  with 
Mycobacterium tuberculosis. Tuberculin skin testing is done using a purified protein derivative (PPD) 
whose strength is usually expressed in terms of Tuberculin Unit.  The commercially available PPD 
preparation is defined as the dose of that product which is biologically equivalent to that contained in 5 
Tuberculin unit of PPD-S ( PPD –Seibert) i.e., it elicits skin reaction of same size as PPD-S with a error 
of 20%.24 One Tuberculin 
Unit of Purified Protein Derivative RT 23 with Tween 80 corresponds fairly well to 3 TU of PPD-S. 
Therefore,  2TU of  PPD  RT 23  with  Tween  80  is  used  for  diagnosis  or  survey.26  Tween  80  is  a 
stabilizing agent to prevent the absorption of tuberculin to glass surfaces. Purified protein derivative 
(PPD) RT 23 with Tween 80 is prepared from Mycobacterium tuberculosis by Statens Serum Institute, 
Copenhagen in Denmark and the seed lot is supplied in freeze dried form to laboratories of individual 
countries. Other tuberculin available in the market may not be standardized.
Tuberculin vials should be always stored at 2°C - 8°C and used before the expiry period, which 
is about one year after reconstitution and dilution. Exposure to sunlight and heat must be avoided.27 The 
tuberculin should not be allowed to freeze or kept at temperatures above 20oC except for very short 
period.
4.2.1.2 Administration of the Test
Tuberculin is injected in a measured amount of 0.1 ml intradermally on the mid-volar aspect of 
the forearm (Mantoux Method). Conventionally the test is given on the left forearm to avoid errors in 
reading. However, right arm can be used in case of any contraindication to use the left arm. 
The skin is lightly stretched and the needle point is inserted with the bevel pointing upwards 
into the superficial layers of the skin. The area  chosen  should  be  free  of  scars,  veins  and  any 
inflammation. The test site need not be sterilized before injection.28 It can be simply washed with soap 
and water and dried before injection. The injection is given with the standard 1 ml tuberculin syringe 
graduated to hundredth of a millimeter fitted with 26-gauge needle of half an inch length and 20 o bevel. 
A glass tuberculin syringe or a disposable tuberculin syringe can be used.  No other syringe like a 
insulin syringe should be used for this purpose.
A satisfactory test should raise a flat pea-sized wheel of diameter 6mm to 10mm with clear pits 
of hair follicles. There should be no leaking of tuberculin. If the test is unsatisfactory i.e., the correct 
amount has not been injected or the injection has been made into the subcutaneous tissue , then another 
injection can be given either at a sufficient distance from the first injection site or in the other forearm.
In  some atopic  individuals,  an  urticarial  wheel  may appear  within  minutes  of  injection.  It 
usually disappears within 1 to 2 hours. The formation of vesicle, bullae, lymphangitis, ulceration or 
necrosis at the site, which may occur in a proportion of children, indicates a high degree of tuberculin 
sensitivity.29
4.2.1.3 Reading of the Test
The  injection  of  the  tuberculin  antigen  leads  to  migration  and  proliferation  of  sensitized  T-cell 
lymphocytes  to  the  test  site.  These  T-cells  release  lymphokines,  which  further  attracts  other 
lymphocytes and monocytes.30 This reaction along with the increased permeability of the local blood 
capillaries leads to an induration at the test site. The size of this induration is maximum between 48-96 
hours after the test .31   The reading of the test is done by measuring the transverse diameter of this 
induration during this period.31 The reading of the test should be done in good day light with flexed 
forearm, by carefully palpating the site of injection using one finger. The test result should never be 
recorded as “positive” or “negative” and must always be recorded in millimeter of size. Record should 
also be of formation of vesicles, bullae, lympangitis, ulceration and necrosis at the test site.
4.2.1.4 Interpretation of Tuberculin Test
Population surveys have shown that there are two groups of individuals in any community, one 
consisting of those “infected with M.tuberculosis bacilli”, the rest have no tuberculin sensitivity or 
sensitivity due to some other causes. The majority of the reactions above a particular cut off point  
obtained from tuberculin surveys in respective areas signify infection with tuberculosis bacilli and the 
majority of the reactions below the cut off are due to other causes. However there is some degree of 
overlapping between the infected group and the rest even around the cut off points. Therefore at any 
given cut off point some true infections will be missed and some falsely included. These cut off points 
as  obtained during  epidemiological  surveys  have  been found to  vary between 10mm to  15mm in 
different parts of the country.32 However it is impractical to conduct 
tuberculin surveys all over the country to find suitable cut off points in respective areas. Therefore, the 
interpretation of reactions in 10mm- 14mm range requires more careful interpretation.32 
 Summary of Interpretation of the Tuberculin Test30
Size of Indurations 15mm or above
- Signifies infection with tubercle bacilli irrespective of BCG vaccination status
Size of Indurations between 10mm- 14mm
- Could be attributable to one of the following causes
a. Cross reactivity induced by environmental mycobacteria
b. BCG vaccination induced sensitivity
c. Infection with tubercle bacilli
It is more likely to be attributable to infection with tubercle bacilli in case of history of contact  
with  infective  cases  of  pulmonary tuberculosis,  clinically  confirmed TB,  or  X-ray findings 
suggestive of tuberculosis.
Size of Indurations between 5mm- 9mm
- Majority of such reactions are attributable to cross-sensitivity induced by environmental 
mycobacteria and/ or vaccination with BCG
- It  could  also  be  attributable  to  infection  with  tubercle  bacilli  in  the  presence  of 
immunosuppression
Size of Indurations less than 5mm
-   Indicates absence of any type of mycobacterial infections except in children with severe type 
of immune-suppression
4.2.1.5 Causes of False Negative Reactions to TST 33
a. Infections ( viral  infections like measles,  chicken pox and HCV, bacterial  like recent or 
overwhelming tubercular infection, leprosy,brucellosis,associated fungal infections).
b. Faulty technique
c. Improper storage and dilution of tuberculin
d. Desensitization due to load of antigens as in military tuberculosis and tubercular meningitis
e. Attenuated vaccination against viral infections like measles,mumps,polio
f. Metabolic derangements 
g. Chronic renal failure
h. Protein energy malnutrition
i. Lymphoreticular disorders
j. Lack of available circulating T-lymphocytes
k. Presence of abnormally high number of circulating T-suppressor cells at the site of skin test
l. Intake of corticosteroids, immunosuppressive drugs
m. Extremes of ages ( newborn or elderly)
n. Stress (surgery, burns, grafts vs. host disorders
o. Denatured or contaminated tuberculin
p. Errors in reading / recording
4.2.1.6 Causes of False Positive Test
4.2.1.6.1 Infection with Non-Tuberculous Mycobacteria
Infection with environmental mycobacteria also causes sensitization of the host. The sensitivity 
induced by these  environmental  mycobacteria  that  are  generally non-pathogenic,  cross  reacts  with 
tuberculin  and  is  known as  non-specific  sensitivity  (NSS).  This  non-specific  sensitivity  is  highly 
prevalent in most parts of India as in other non tropical countries. During the tuberculosis prevention 
trial at Chingelpet, India, 61% of children were found to be infected with environmental mycobacteria 
by the age of 9 years and almost all by 19 years.34  Therefore, much of tuberculin sensitivity in the 
community  is  due  to  frequent  contact  with  ubiquitous  environmental  mycobacteria.  However, 
sensitivity  induced  by  these  mycobacteria  will  lead  to  smaller  reactions  to  tuberculin  than  from 
infection with tubercle bacilli.35 
4.2.1.6.2 Effect of Vaccination with BCG
The effect of vaccination with BCG on subsequent tuberculin skin test is highly variable as it 
partly depends on the strain of BCG used. In a study conducted by National Tuberculosis Institute in 
Bangalore (India), 70% of the children aged 0-9 years, 
vaccinated under Universal Immunisation Programme, elicited either no reaction or a reaction less than 
10mm.36 Some studies have shown that the effect of vaccination with BCG on tuberculin skin test 
actually wanes over time.37, 38 Seth et al have demonstrated that, there is 50-60% waning in the first year 
itself.37  Wang et al, in a meta-analysis , showed that vaccination with BCG significantly increases the 
likelihood of a positive tuberculin skin test.  38  They also showed that the effect of vaccination with 
BCG on TST was less after duration of 15 years and the reactions more than 15mm are more likely to 
be the result of tuberculosis infections rather than the BCG vaccination.38 
4.2.1.6.3 Booster Phenomenon
On sequential tuberculin testing some persons show a marked increase in the size of their skin 
reactions that may not be due to recent or past infections. This is called “booster” phenomenon. The 
increase seems to occur as the initial test stimulates the factors that determines reaction size in the 
subsequent test.39
4.2.2 Other Tuberculin Test
4.2.2.1 Scariform Test40
There are two types of scariform tests – Von Pirquet Test and Trumbusti Test.
Von Pirquet Test
This test was first used by Clemens von Pirquet in 1907 for detecting allergy to tuberculin. It as 
described as the first safe method of detecting allergy to tuberculin. Two drops of 25% dilution of Old 
Tuberculin (OT) and two drops of control diluents was placed side by side over the test site in one  
forearm. Superficial scratches are made with a sharp knife or lancet of equal length and depth, through 
the diluents over the skin of the forearm. The tests are read after two days. A swollen linear scar of 3-
4mm width through the OT indicates a positive reaction. The limitation of this test is that it does not 
measure allergy quantitatively.
Trumbusti Test
This test is a slight modification of the Von pirquet test. A single puncture is made through the 
concentrated drop of OT with a wide bore needle with a beveled edge and needle is turned two to three 
times so that a small puncture is cut by it. Tuberculin is allowed to dry on the spot. The test is read 2-3  
days later.
4.2.2.2 Moro Patch Test40 
               Around 1908 Moro introduced the percutaneous patch test. Old Tuberculin jelly is placed on 
the skin of the arm or back and is covered with a plaster.  A control test with only the jelly is placed  
next to the test. Both plasters are removed after a day and both tests are read 2-5 days later. Volmer in  
1937 still modified the patch test in which the Old 
Tuberculin was dried on adhesive tape and was stuck to the skin.  A control patch was applied. The 
patches were removed after 48 hours and the test were read.   All these tests were not quantitative.
4.2.2.3 Multiple Puncture Test40
              This is a modification of the Von Pirquet’s and Trumbusti tests. There were multiple punctures  
instead of two punctures. 
4.2.2.4 Heaf Test40 
This test was introduced by Fredrice Heaf and is called Heaf’s Modified Multiple Puncture 
test. This test was further improved by Rosenthal and Heaf himself. In this test adrenalised tuberculin is 
sprayed on the skin by using a platinum loop. An instrument called the Heaf’s gun is used to puncture 
the skin with 6 or more needles arranged in a circular metal head 6mm in diameter. The test can be read 
up to 7 days and is hence called the ‘market day test’. Red dots at the test site indicate positivity.
4.2.2.5 Stern Needle Test
The stern needle test is a modification of Heaf Test. It uses detachable metal heads, which 
can be sterilized in bulk.
4.2.2.6 The Tine Test
This  test  is  done  with  individually prepared  sterilized  units.  Old  Tuberculin  is  dried  on 
sterilized tine point and used once and discarded. This method cannot quantify allergy.
4.2.2.7 The Dermo  Spray Method
This  is  a  modification  of  the  intradermal  test  technique  as  designed  by Krantz.  He  designed  an 
apparatus that can inject exactly 0.1 ml of fluid through a capillary under high pressure. The high-speed 
jet of fluid automatically pierces the skin and produces a pale wheel as in a good Mantoux test. Since 
the apparatus does not use a needle to pierce the skin, it is enough to sterilize the entire apparatus 
before each session.
TABLE NO. 1  Latent tuberculosis infection(LTBI) prevalence studies in population using TST
Sr. 
No
Area & Study Population Sample size Type  of 
Tuberculin
Site of Testing Level  of 
Demarcation
Prevalence  of  Latent 
Tuberculosis Infection
1 0-60+ age group of Tumkur 
district (1960-61)41
26062 1  TU  RT  23 
with  Tween 
80
Mid  Volar 
surface of left 
forearm
≥  10mm Overall 38.3% 
(  Male  42.8,  Female 
33.9 ) 
2 0-55+ age group of Magadi 
Chanapatna,Nelamangala  of 
Bangalore district .Total 119 
villages  (1961-68).  Four 




3rd Survey – 46545
4th Survey – 47207
1  TU  RT  23 
Tween 80
Right  or  Left 
forearm  ; 
alternating the 
area  at  each 
survey  but 
choosing  a 
different  site 
for the test
≥  10mm 1st Survey  –Overall 
29.5%
2nd Survey-  Overall 
30.4%
3rd Survey  –  Overall 
29.3%
4th Survey  –  Overall 
30.4%
3 0-60+  years  of 
Neelamangala subdivision of 
Bangalore  district  1968-
197242
29962 1 TU PPD RT 
23  with 
Tween 80
Not available ≥  12mm Overall 35.2%
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Sr. No Area & Study Population Sample 
size
Type  of 
Tuberculin
Site  of 
Testing
Level  of 
Demarcation




4 All ages of Chingelpet district of 
Tamilnadu in the year 197144
2,63,842 3 TU 0f PPD-S Mid  dorsal 
aspect  of 
forearm
≥  12mm Overall 50%
5 0-55+  age  group  of 
Magadi,Chanapatna,Nelamangala 
taluks of Bangalore district
1977-7845
8025 1TU PPD RT 23 
with Tween 80
The  upper 
third  of  the 
dorsal  aspect 
of  the  right 
forearm
≥  16mm Overall 65.2%
6 All  ages  of  Srinagar,  Bramulla 
and Anantnag district of Kashmir 
valley in the year 197846
12832 3TU of PPD-S Mid  dorsal 
aspect  of  the 
forearm
≥  12mm Overall 38%
The above table shows the various prevalence studies on latent TB infection in India. The prevalence of latent TB infection range from 
29.5% to as high as 65.8%.
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TABLE NO. 2    Prevalence of LTBI among contacts of Infective Tuberculosis
Sr. No Area & Study Population Sample size Type  of 
Tuberculin
Level  of 
Demarcation
Prevalence of Latent Tuberculosis 
Infection
1 Chandigarh  ,  Under  5 
contacts  of  sputum 
positive patients47
140  contacts  and 
141  contacts  of 
sputum  negative 
patients
1 TU of  PPD 
RT  with 
Tween 23
> 10 mm 46.4%  in  contacts  of  sputum 
positive cases
21.2%  in  contacts  of  sputum 
positive cases
2 Sevagram, Gujrat(2004)
Among  health  Care 
Workers48
720 1 TU of  PPD 
RT  with 
Tween 80
≥  10 mm 41.3%  among  all  health  care 
workers 
This table shows the prevalence of among contacts. The prevalence is between 41.3% and 46.4%.
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4.2.3 New alternative test to diagnose LTBI
In the absence of a gold standard to diagnose latent tuberculosis infection, it may 
be difficult to demonstrate that any test is better than the tuberculin skin test. However, 
the sensitivity of a potential test may be predicted by correlating its result with the degree 
of exposure (duration and proximity) to a source patient and the likelihood of acquiring 
infection from that source. A test would be more sensitive than the tuberculin skin test if 
it  is  positive in  patients  with a  high  risk of  exposure.  A more specific  test  could be 
independent of vaccination with BCG.
Recently new immune – based blood tests were developed for the diagnosis of 
latent  tuberculosis.  These  tests  measures  interferon  gamma  released  in  response  to 
stimulation of sensitized T-cell  by mycobacterial  antigens.49 The best studied of these 
antigens are Early Secretory Antigenic Target-6 (ESAT-6) and Culture Filtrate Protein- 10 
(CFP-10). These tests are called Interferon Gamma Release Assay (IGRA) tests. There 
are two commercially available diagnostic tests incorporating specific antigens. They are 
QuantiFERON  TB  Gold  (Cellestis,  Australia)  and  T-SPOT  –TB  Assay  (Oxford 
Immunotech, UK).
The sensitivity of IGRA tests were studied in patients with active tuberculosis and 
contacts of infectious tuberculosis patients.  From these studies, in patients with active 
tuberculosis  disease ,  IGRA tests  were found to  have a  sensitivity of  74-96%, while 
tuberculin skin test (TST) had a sensitivity of 64-69%.51,52,53 In contact tracing studies, 
IGRA tests  were  found  to  be  as  sensitive  as  TST  for  detecting  latent  tuberculosis 
infection and, in some studies, they correlated better with the degree of exposure.54, 55, 56
22
  However, in immunocompromised patients, the data is too scarce to make any 
definite conclusions regarding the agreement between the two tests. One study of 590 
HIV- infected patients showed that QuantiFERON TB Gold (QFT-G) test correlated with 
known risk factors for latent tuberculosis infection or past history of tuberculosis.56 
The  gold  standard  proof  of  latent  tuberculosis  infection  is  the  eventual 
development of active tuberculosis disease. This can be observed by conducting a 
longitudinal study where tested individuals are followed up for development of active 
tuberculosis  disease.  Diel et  al,  in Germany evaluated 601 close contacts of infective 
tuberculosis patients of whom 278(46.3%) had vaccination with BCG.57 Tuberculin skin 
test  was  positive  in  243(43%),  while  QFT-G was  positive  in  66(11%)  contacts.  All 
contacts were followed for 2 years.  Six of the contacts  developed active tuberculosis 
disease during follow-up and all six were QFT-G positive. None of the QFT-G negative 
individuals developed tuberculosis. This important study concluded that QFT-G is a more 
accurate predictor of latent tuberculosis infection than tuberculin skin test (TST).
IGRA tests have several operational advantages over tuberculin skin tests. They 
require only one visit for blood smpling.57  Automated reading reduces the reader bias in 
interpretation. There is no booster effect of the test and, therefore, repeated testing (e.g.,  
in health care workers) does not affect results.57  The test is read in 24 hours. But IGRA 
tests need some base laboratory and some technical skills. 
The main advantage of IGRA tests is their specificity compared to TST.57 This 
significantly eliminates false positive results in BCG vaccinated individuals and therefore 
avoids the cost and toxicity associated with unnecessary treatment.  The sensitivity of 
IGRA tests are found to be similar as TST from studies.54, 55, 56 In contact tracing studies, 
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they showed good correlation with the degree of exposure to an index case. 54,55,56 In some 
studies,  sensitivity  of  IGRA  tests  was   found  to  be  better,  particularly  among 
immunocompromised  patients.56   Detection  of  latent  tuberculosis  infection  in  these 
patients  is  highly  important  because  of  their  increased  risk  of  progression  to  active 
disease. 
The main disadvantage of any IGRA test is their cost. A single assay usually cost 
around $ 30-40. The cost to the healthcare system may initially increase but the overall 
cost  will  decrease,  as  less  latent  tuberculosis  patients  are  treated  and  less  visits  are 
required. The question is whether IGRA tests should complement or replace TST. The 
TST is cheap and sensitive for diagnosing latent tuberculosis infection. However, in BCG 
vaccinated individuals, its specificity is clearly inferior to that of IGRA tests. The 
expensive IGRA test may not be affordable by many developing countries. Therefore, it 
is likely that TST will remain in use in many parts of the world.
In  resource-  rich  countries,  IGRA  tests  are  increasingly  utilized.  In  their, 
guideline, the Centre for Disease Control and Prevention (USA) has suggested replacing 
TST with QuantiFERON TB Gold  59   On the other hand British guideline recommend 
using  IGRA tests  as  confirmatory  tests  in  those  with  positive  TST results.60   A cost 
analysis  study  in  Germany  found  that  screening  of  contacts  by  TST  followed  by 
QuantiFERON TB Gold  Assay in  positive  TST reactors  was  the  most  cost-effective 
method for screening for latent tuberculosis infection.57
4.2.3.1 QuantiFERON TB GOLD Assay61
QuantiFERON TB Gold In- Tube (QFT) is  an in vitro diagnostic test  using a 
peptide cocktail simulating ESAT-6 , CFP-10 and TB-7 proteins to stimulate cells in the 
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heparinised whole blood to release interferon. Detection of interferon-  γ  (IFN-γ  )  by 
Enzyme Linked Immunosorbent Assay (ELISA) is used to identify in vitro responses to 
these peptide antigens that are associated with Mycobacterium tuberculosis infection.
QFT is  an indirect  test  for  M.tuberculosis  infection (including disease)  and is 
intended to be used in conjunction with risk assessment, radiography and other medical 
and diagnostic evaluation.
4.2.3.2 Steps of QuantiFERON TB GOLD Test61
a. Patient’s blood is collected into blood collection tubes and is mixed by shaking 
the tubes up and down 10 times to ensure that the entire inner surface of the tube 
is coated with blood.
QFT TB Gold uses two types of tube for collection of blood namely
- Grey cap tube containing nil control
- Red cap tube containing TB Antigen
b. After collection of the blood into the container it is transferred to an incubator as 
soon  as  possible  and  latest  within  16  hours  of  collection.  The  sample  is  not 
refrigerated or freezed. The tubes are incubated upright at 37°for 16-24 hours. The 
incubator does no require carbon dioxide or humidification. After incubation at 
37°for 16-24 hours, the blood collection tubes may be held between 2 to 27o C for 
up to 3 days prior to centrifugation.
c. After incubation of the tubes at 37o  C, harvesting of the plasma is facilitated by 
centrifuging the tubes for 15 minutes at  2000 to 3000 RCF (g).  The gel  plug 
25
separates  the  cells  from the  plasma.  If  this  does  not  occur,  the  tubes  are  re-
centrifuged at a higher speed. This will separate the plasma and the red cells.
d. Plasma samples are loaded directly from blood collection tubes into the QFT-TB 
Gold ELISA Plates, especially when automated ELISA workstations are used.
e. All  plasma samples  and  regents,  except  for  conjugate  100X Concentrate,  are 
brought to room temperature (22 – 25o C) before use.  At least 60 minutes are 
allowed for equilibrium.
f. The freeze dried “kit standard” is reconstituted with equal volume of deionised or 
distilled water indicated on the label of the standard vial. It is mixed gently to 
minimize frothing and to  ensure complete  solubilisation.  Reconstitution of the 
standard to the stated volume produces  a solution with a concentration of 8.0 
IU/L. The reconstituted kit standard is used to produce a 1 in 4 dilution series of 
IFN-γ  in Green Dilution (GD). 
g. S 1 (Standard I) contains 4 IU/ml , Standard 2 ( S2) contains 1 IU/ml , S3 contains 
0.25 IU/ml and S4 contains 0 IU/ml ( Green Dilution).
h. The  freeze  dried  conjugate  100X Concentrate  is  reconstituted  with  0.3  ml  of 
deionised or distilled water. It is mixed gently to minimize frothing and to ensure 
complete solubilisation of the conjugate.
i. Prior  to  assay,  plasma  is  mixed  to  ensure  that  IFN-γ  in  evenly  distributed 
throughout the sample.
j. 50  µL of freshly prepared Working Strength Conjugate is added to the required 
ELISA wells using a multichannel pipette. 
k. 50 µL of test plasma samples is added to appropriate wells using a multichannel 
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pipette. Finally, 50µL each of the Standards 1 to 4 is added.
l. The conjugate and plasma samples / standards are mixed thoroughly using   micro 
plate shaker for 1 minute.
m. Each plate is covered with a lid and incubated at room temperature ( 22o C +- 5oC) 
for 120 +- 5 minutes.
n. During the incubation, one part Wash Buffer 20X conjugate is diluted with 19 
parts  deionosed or distill  water  and mixed thoroughly.  It  is  washed well  with 
400µL of working strength wash buffer for at least 6 cycles. An automated plate 
washer is used. 
o. Residual wash buffer is removed by making the plates face down on an absorbent 
towel.  100µL of Enzyme Substrate Solution is  added to each well  and mixed 
thoroughly using a microplate shaker.
p. Each plate is covered with a lid and incubated at room temperature ( 22o C +- 5oC) 
for 30 minutes. Plates are not exposed to direct sunlight during incubation.
q. Following 30 minutes of incubation, 50µL of Enzyme Stopping Solution is added 
to each well and mixed. Enzyme Stopping Solution is added to the wells in the 
same order and at approximately the same speed as the substrate. 
r. The Optical Density (OD) of each well is measured within 5 minutes of stopping 
the reaction using a microplate reader fitted with a 450nm filter and with a 620-
650nm reference filter. Optical Density values are used to calculate the results.
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4.2.3.3 Calculations and Test Interpretation61 
QFT –TB Gold IT Analysis software is used to analyse raw data and calculate 
results. This software is available with Cellistis, Australia. If this software is not used, 
results can be obtained manually.
The mean OD values of the kit standard replicates on each plate are determined. A 
standard curve is constructed by plotting the log (e) of the mean OD in the y-axis against  
the log (e) of the IFN-γ  concentration of the Standard in IU/ml in the x-axis, omitting the 
0 standard from the calculation. The line of best fit for the standard curve is calculated by 
regression analysis.  The standard curve is  used to determine the IFN-γ  concentration 
(IU/ml) for each of the test plasma samples, using the OD value of each sample.
 TABLE  NO. 3 Interpretation of Results when NIL Tube and TB Antigen are used61
NIL 
(IU/ml)





≤  8.0 < 0.35 Negative M.Tuberculosis  infection 
NOT likely.
≥  0.35 and < 25% of NIL Value Negative M.Tuberculosis  infection 
NOT likely.
≥  0.35 and ≥  25% of NIL Value Positive M.Tuberculosis  infection 
likely.
> 8.0 Any value Indeterminate Results are indeterminate for 
TB Antigen responsiveness.
The above table shows the interpretation of QFT-G test results when the software is not 
available.
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4.2.3.4 Cautions and Limitations of Using QFT59
Certain  limitations  of  QFT-TB Gold are similar  to  that  of  the  TST,  but  these 
limitations have not been studied extensively for QFT-TB Gold. Whereas the sensitivity 
of QFT-TB Gold for detecting M. tuberculosis infection in persons with untreated culture 
confirmed  TB  is  approximately  80%  in  published  studies,  the  QFT  sensitivity  for 
particular group of TB patients (eg., young children and immunocompromised patients) 
has not been studied. 
QFT-TB Gold sensitivity for detecting latent tuberculosis infection might be less 
than that of the TST, although the lack of confirmatory test to detect latent TB infection 
makes it difficult to assess this. Estimating the sensitivity of any indirect test for latent  
TB infection, like testing the patients who have tuberculosis disease, might be inaccurate 
because of differences between these conditions. The ability of QFT to predict risk for 
progress to tuberculosis disease has not been determined. 
QFT, as with the TST, cannot differentiate infection associated with TB disease 
from latent tuberculosis infection. A diagnosis of latent tuberculosis infection requires 
that  tuberculosis  disease  be  excluded  by  medical  evaluation,  which  should  include 
checking for suggestive signs and symptoms, a chest radiography, and, when indicated 
examination of sputum or other clinical sample, the presence of M. tuberculosis.
Similar to any other diagnostic test, the predictive value of QFT results depends on the 
prevalence of M.tuberculosis infection in the population being tested. Each QFT result 
and  its  interpretation  should  be  correct  in  conjunction  with  other  epidemiological, 
historic, physical and diagnostic findings.
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As with a negative TST result, negative QFT result should not be used alone to 
exclude  M.tuberculosis  infection  in  persons  with  symptoms  or  signs  suggestive  of 
tuberculosis  disease.  The  presence  of  symptoms  or  signs  suggestive  of  TB  disease 
increases  the  likelihood  of  M.tuberculosis  infection,  and  this  decreases  the  negative 
predictive value of QFT or TST test in detecting latent tuberculosis infection. Medical 
evaluation  of  such  persons  should  include  a  history and  physical  examination,  chest 
radiographs, bacteriological studies, serology for human immunodeficiency virus (HIV), 
and, when indicated , other tests or studies.
The performance of QFT ,  in particularly its  sensitivity,  and its  rate of indeterminate 
results, has not been determined in persons who, because of impaired immune function, 
are  at  increased  risk  for  M.tuberculosis  infection  progressing  to  tuberculosis  disease. 
Impaired  immune  function  can  be  caused  by  HIV  infection  or  acquired  by 
immunodeficiency syndrome (AIDS); current treatment with immunosuppressive drugs 
including  high  dose  corticosteroids,  tumor  necrosis  factor-α (TNF-α)  antagonist  and 
drugs used for managing organ transplantation; selected hematological disorders ( e.g., 
myeloproliferative  disorders,  leukemias  and  lymph  node  specific  malignancies); 
diabetes ; silicosis; and chronic renal failure. Each of these conditions or limitation is 
known or  suspected  to  decrease  responsiveness  to  the  TST,  and that  might  decrease 
production of IFN-γ  in  the QFT assay.  Consequently,  as with a  negative TST result, 
negative QFT alone might not be sufficient to exclude M. tuberculosis infection in these 
persons.
Published data are relatively limited concerning the use of QFT among persons 
recently exposed to tuberculosis ( i.e., close contacts) and other populations at high risk 
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for latent tuberculosis infection. No published data document the performance of QFT in 
children aged < 17 years.
With any of the testing methods, persons who have a negative result can still have 
latent tuberculosis infection. Those who have negative but who are likely to have latent 
TB infection and those who are at a greater risk of developing severe illness or poor 
outcome from TB disease need treatment or close monitoring for disease.  
Potential examples include close contacts who aged less than 5 years; or those who are 
immunocompromised due to HIV infection or those on any immunosuppressive therapy.
QFT has practical limitations that include the need to draw blood and to ensure its 
receipt in a qualified laboratory in time for testing. The blood must be incubated with the 
test antigens < 12 hours after collection to keep the lymphocyte viable. After the blood is 
incubated with antigens for 16-24 hours, plasma must be collected and either properly 
stored or tested promptly by ELISA. Collecting the required 5 ml blood sample from 
young children might not be possible or acceptable
4.2.3.5 Agreement Between Tuberculin Skin Test & QuantiFERON TB Gold
Since there is no gold standard test to diagnose latent tuberculosis infection it is 
difficult to accurately measure the sensitivity or specificity of any test. TST has been used 
for a long time as a standard test to detect latent tuberculosis infection. So the new test 
QuantiFERON TB Gold is evaluated based on an agreement i.e concordance with TST in 
healthy populations with varying risk for latent tuberculosis infections. Some of these 
studies are summarized in the following table no.4.
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TABLE NO.4   Agreement between QuantiFERON and TST in healthy population 
with varying risk for LTBI
Study, Year
Reference
Country Risk Group Total Participants BCG Vaccinated
( in % )
Brock et al.,
2004










Korea Close  &  casual 





USA Prisoners 409 -
Ferrara et al.,
2006
Italy Hospitalised adults 286 18
Harada et al.,
2006






Country Risk Group Total Participants BCG Vaccinated








South Africa Healthy adults 358 81
Tsiouris et al.,
2006
South Africa Pediatric contacts 184 73
Lee et al.,
2006
Korea Healthy students 131 100
Nakaoka et al.,
2006
Nigeria Pediatric contacts 179 37
Connell et al.,
2006
Australia Pediatric contacts 75 49
Table 4 shows the various studies comparing the agreement between TST and 
QFT-G. The agreement between the tests varies from as low as 13% to as high as 94%.
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5. MATERIALS AND METHODS
5.1 Study  Design
The study was done by a cross sectional design. 
5.2 Study  Area
The study area comprises of population covered by two Tuberculosis Units (TU) 
in  Vellore  district:  CHAD  TU  and  DTC  TU  .CHAD  (Community  Health  and 
Development ) is a 140 bedded hospital run by the Department of Community Health of 
the Christian Medical College, Vellore. This CHAD TU comprises of 12 peripheral health 
institutes (PHI) which include CHAD hospital, Narayani hospital and 10 primary health 
centre (PHCs) run by the government. This TU covers around 6 lakhs population. The 
other  Tuberculosis  Unit  (TU)  is  based  at  District  Tuberculosis  Centre,  Vellore  and 
comprises of 11 PHIs. This includes Christian Medical College and Hospital and 10 other 
PHCs. This TU covers around 5.5 lakhs populati
5.3 Sample Size
Sample size was calculated using the formula 
N = 4PQ / d2
Where N= sample size required
P=  prevalence  of  latent  tuberculosis  infection  among  contacts  from 
previous studies
Q = 100-P
d= Relative Precision  taken as 20% of Prevalence
Taking prevalence P as 40%73  the sample size was calculated as 150.
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5.4 Study Population and Sampling Method
Among all the suspected MDR patients in these two TUs a total of 147 were done 
sputum culture. Out of this 147 patients , 104  found culture positive for M.Tuberculosis. 
Out of 104 sputum culture positive patients 48 were selected based on the distance of 
these houses from CHAD within Vellore corporation limits and Kaniyambadi block. 44 
of  them agreed  to  participate  in  the  study.  From this  44  index  cases  a  total  of  154 
contacts were identified and subjected to both the tests.
Exclusion Criteria
• Person already diagnosed as having tuberculosis
• Those with signs and symptoms suggestive of  tuberculosis
• Those already on chemoprophylaxis for tuberculosis
• Persons known to be immunocompromised
• Children less than 1 year of age
Out of the 38 index cases contacted, 34 agreed to participate in the study. The 
total number of contacts of these 34 index cases was 154.
5.5 Informed Consent
Information sheet and consent form was written in Tamil and was approved by the
Institutional ethics committee. Informed consent was taken from individual subject. For 
those who are minor consent was taken from the guardian. 
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5.6 Methodology
2 Tuberculin Unit (2TU) PPD RT 23 with Tween 80 was used for this study. The 
standard  2TU  PPD  is  manufactured  by  Statens  Serum  Institute  (SSI),  Copenhagen, 
Denmark and is not generally licensed for use in India. A license to import and use 2TU 
PPD from SSI, Copenhagen was obtained from the  Drugs Controller General of India.
Two medical laboratory technicians were selected to do the testing and reading. 
Both the technicians underwent a 7 days training on testing and reading tuberculin skin 
test  under  the  guidance  of  Dr.A.N.Sashidhara,  Senior  Field  Investigator  at  National 
Tuberculosis Institute, Bangalore.
The  houses  were  visited  and  formal  written  consent  was  taken.  A structured 
questionnaire was administered for obtaining socio demographic parameters.
Blood was collected by venepuncture from cubital vein after cleaning the site with 
normal saline. The samples were collected into the labeled sample collection tube upto 
the required marks and were kept at ambient temperature.
The mid volar aspect of right forearm was selected for tuberculin skin testing. The 
site was identified and cleaned with normal saline. 1 ml 2TU PPD was loaded in the 
tuberculin  syringe.  The  skin  was  stretched  and  the  2TU  was  applied.   In  case  of 
unsatisfactory test the procedure was repeated further away from the first site.
The tuberculin  skin  test  was read  between 48-  72 hours  and the  results  were 
reported in millimeter. Any unusual reactions such as abscess, ulceration, necrosis, were 
also recorded. 
Children less than 15 years with indurations  ≥  10mm were referred to CHAD 
hospital for further investigations and management. 
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5.7 Statistical Analysis
The data were entered  and  analyzed using EPI INFO 2002  software.
The  primary  outcome  measured  was,  the  prevalence  of  latent  tuberculosis 
infection using tuberculin skin test with a cut off 10mm and QFT cut off 3.5IU/ml. The 
data  were  further  stratified  into  pediatric  (<15  years)  and  adult  age  group  and  the 
prevalence was estimated. 
The TST and QFT response was further  analyzed in relation to  age,  sex and, 
proximity of contact (as measured by sleeping in same or different house as the index 
case) individually . The association was expressed in terms of chi square and p value .The 
agreement (both percent agreement and kappa agreement) between TST and QFT was 



































6.1   General Profile
6.1.1 Characteristics of the study population.
Total number of subjects in the study was 150. Out of this 150, 64 were male 
constituting 42.7% of the population and 86 were female comprising 57.3% of the 
population.
 TABLE NO.5   Age and sex distribution of the study population.
AGE/SEX MALE FEMALE TOTAL
PEDIATRIC 33 (66%) 17 (34%) 50(100%)
ADULT 31 (31%) 69 (69%) 100(100%)
TOTAL 64 86 150
Table 5 shows the age- sex distribution of study population. The total number of 
subjects in the pediatric age group (< 15 years) is 50 out of which 33(66%) are male and 
17(34%) are female. The total number of subjects in the adult age group is 100 out of 
which 31(31%) are male and 69(69%) are female.  
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TABLE NO.6   BCG scar status of the study population
AGE GROUP SCAR PRESENT SCAR ABSENT TOTAL
PEDIATRIC 36 (72%) 14 (28%) 50(100%)  
ADULT 25 (25%) 75 (75%) 100(100%)
TOTAL 61 89 150
Table 6 shows the distribution of BCG scar in the study population in adult and 
pediatric  age  group.  Presence  of  BCG  scar  is  taken  as  a  surrogate  for  BCG 
vaccination. Among the pediatric age, 36(72%) have BCG scar and 14(28%) do 
not have the scar. In the adult population 25(25%) have BCG scar and 75(75%) 
do not have scar. 
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6.2 Overall prevalence of LTBI
TABLE NO.7   Prevalence of LTBI  by TST
Age Group TST Positive TST Negative TOTAL CHI 
SQUARE
P VALUE
Pediatric(<15) 32(64%) 18(36%) 50(100%) 12 0.001
Adult 88(88%) 12(12%) 100(100%
)
TOTAL 120(80%) 30(20%) 150(100%
)
Above table shows that the TST positivity is higher in adult age group and this difference 
is significantly higher in comparison to pediatric age group. 
TABLE NO. 8   Prevalence of  LTBI  by QFT 











0.359 0.545Adult 65(65%) 35(35%) 100(100%)
TOTAL 95(63.3%) 55(36.7%) 150(100%
)
Table  no.  8  shows  that  the  QFT positivity  in  adult  and  pediatric  age  group  is  not 
significantly different.
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TABLE NO.9   Frequency of LTBI  by TST and QFT in different age clusters
Table no.9 shows that TST positivity increases with age whereas QFT positivity remains 
more or less the same which is also seen in figure no. 2 below.
Figure 2   Frequency of Latent TB infection with increasing age
6.2.1  Distribution of TST Indurations in the study
Out of 150 individual  the TST indurations varies from 0 mm to 25 mm. The 
frequency distribution is shown in Figure 3.
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Figure no. 2 shows the frequency distribution of TST indurations in the study sample. 
There is a bimodal distribution with a fair antimode. Two clear cut modes are visible. One 
around the 0 mm mark and another around 20 mm mark.
6.3. Prevalence of Latent Tuberculosis Infection in relation to sex
TABLE NO.10 Prevalence of LTBI  by Tuberculin Skin Test (TST) in relation to sex
Above table shows that in both age groups there is no significant difference in different 
sexes in relation to TST positivity.
TABLE NO.11 Prevalence of LTBI by QFT in relation to sex
Table  No.8  shows  there  is  no  significant  difference  in  different  sexes  in  relation  to 
infection by QFT.
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6.4  Prevalence  of  Latent  Tuberculosis  Infection  in  relation  to  BCG  vaccination 
status










Present 24(66.7%) 12(33.3%) 36(100%)
0.66 0.797
Absent 8(57.1%) 6(42.9%) 14(100%)
Adult
Present 20(80%) 5(20%) 25(100%)
2.02 0.155
Absent 68(90.7%) 7(9.3%) 75(100%)
TOTAL 120(80%) 30(20%) 150(100%
)
Above table shows that there is no significant difference in TST positivity in both ages in 
relation to BCG vaccination status














Present 22(61.1%) 14(28.8%) 36(100%)
0.66 0.797
Absent 8(57.1%) 6(42.9%) 14(100%)
Adult
Present 16(64%) 9(36%) 25(100%)
0.015 0.904
Absent 49(65.3%) 26(34.7%) 75(100%0
TOTAL 95(63.7%) 55(36.3%) 150(100%)
Table 13 shows no difference between BCG vaccinated and unvaccinated in both age 
groups in having latent tuberculosis infection. 
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6.5   Prevalence of Latent Tuberculosis Infection in relation to proximity of contact















Room 19(70.4%) 8(29.6%) 27(100%) 1.034 0.309Same 
House 13(56.5) 10(43.5%) 23(100%)
Adult
Same 
Room 41(97.6%) 1(2.4%) 429100%) 6.345 0.012*Same 
House 47(81%) 11(19%) 58(100%)
TOTAL 120(80%) 30(20%) 150(100%)
* p <0.05
Table no. 14 shows that there is significant difference in latent tuberculosis infection in 
adults sharing the same room with index case by TST .
TABLE NO. 15   Prevalence of LTBI 
 by QFT in relation to proximity of contact
*p<0.05 Table no. 15 shows that there is a significance difference in latent tuberculosis 
infection by QFT positivity in adults  sleeping in same room than those sleeping in a 
different room.
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6.6   Prevalence of Latent Tuberculosis Infection in relation to educational status













TOTAL 88(88%) 12(12%) 100(100%
)
 
Table no. 16 shows that although TST positivity is more in lower educational status, this 
difference is not statistically difference in both educational group.















TOTAL 65(65%) 35(35%) 100(100%
)
Table no. 17 shows that although QFT positivity is more in lower educational status, this 
difference is not statistically difference in both educational groups as in TST.
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6.7   Prevalence of Latent Tuberculosis Infection in relation to occupation
TABLE NO. 18 Prevalence of LTBI  by TST in relation to occupation in adults
Table no.18 shows that the  LTBI in those at home is more than those working, but this  
difference is not statistically significant.
TABLE NO. 19 Prevalence of LTBI  by QFT  in relation to occupation in adults
Table no. 19 shows that the LTBI in those at home is more than those working, but this  
difference is not statistically  significant.
6.8 Agreement between TST and QFT
TABLE NO. 20 Overall Agreements between TST and QFT
QFT POSITIVE QFT NEGATIVE TOTAL
TST POSITIVE 94 26 120
TST NEGATIVE 1 29 30
TOTAL 95 55 150
Table 20 shows that the actual agreement between TST and QFT in detecting 
latent tuberculosis infection is  82% and the kappa agreement is  0.57 (95% CI 
0.434-0.706).
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TABLE NO. 21 Agreement between TST and QFT in BCG vaccinated individuals
QFT POSITIVE QFT NEGATIVE TOTAL
TST POSITIVE 38 6 44
TST NEGATIVE 0 17 17
TOTAL 38 23 61
Table 21 shows that the actual agreement between TST and QFT in detecting 
latent tuberculosis infection in all those who are BCG vaccinated is 90% and the 
kappa agreement is 0.779(95% CI 0.613-0.945).
TABLE  NO.22  Agreement  between  TST  and  QFT  in  BCG  unvaccinated 
individuals
QFT POSITIVE QFT NEGATIVE TOTAL
TST POSITIVE 56 20 76
TST NEGATIVE 1 12 13
TOTAL 57 32 89
Table 22 shows that the actual agreement between TST and QFT in detecting 
latent tuberculosis infection in all those who are BCG unvaccinated is 76% and 
the kappa agreement is 0.411(95%CI 0.223-0.599).
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TABLE NO. 23  Agreement between TST and QFT in Pediatric Age Group
QFT POSITIVE QFT NEGATIVE TOTAL
TST POSITIVE 30 2 32
TST NEGATIVE 0 18 18
TOTAL 30 20 50
Table  no.  23 shows the actual  agreement  between TST and QFT in detecting 
latent  tuberculosis  infection  in  pediatric  age  group  is  96%  and  the  kappa 
agreement is 0.915(95% CI 0.797- 1.033).
TABLE NO. 24   Agreement between TST and QFT in Adult Age Group
QFT POSITIVE QFT NEGATIVE TOTAL
TST POSITIVE 64 24 88
TST NEGATIVE 1 11 12
TOTAL 65 35 100
Table 2 shows the actual agreement between TST and QFT in detecting latent 




Tuberculosis  is a major public health concern in the world and particularly in 
India. In countries with high incidence of tuberculosis, the priority is early case 
detection and treatment. Now there is an increasing concern about the benefits of 
contact investigation to detect people with latent tuberculosis infection, more so 
with the spread of MDR tuberculosis. The other issue is, which test to use for 
detecting latent tuberculosis.
The present study was done in keeping two objectives in mind – first, to 
detect the prevalence of latent tuberculosis infection in  contacts of sputum culture 
positive  tuberculosis  among  suspected  MDR  cases  and  secondly,  to  find  the 
agreement between TST and QFT in detecting the latent tuberculosis infection.
The  study was  conducted  among the  household  contacts  of  44  culture 
positive tuberculosis patients. The total number of contacts screened were 150 out 
of which 64(42.6%) were male and 86(57.3%) were female. The total number of 
patients in the pediatric age (less than 15 years) were 50(33.3%) out of which 33 
were male and 17 were female. In the adult age group, a total of 100 subjects were 
there, out of which 31 were male and 69 were female.
7.1   Prevalence of Latent TB Infection
Considering  the frequency distribution  illustrated in  figure 3,  it  can be 
seen that  the entire  range of  reactions  have  clustered  themselves  to  form two 
distinct  groups.  Both  the  modes  and  antimode  can  be  identified.  Persons 
constituting first mode around 0 mm, by and large, are either not reacting at all or 
reacting  very  weekly  whereas,  persons  constituting  the  second  mode,  around 
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20mm, are found to be strongly reacting and so they could be logically assumed 
to compromise of positive reactors specific to tuberculosis infection.  From the 
TST frequency distribution it can be concluded that the TST distribution in the 
study population more or less follows the same pattern as in general population.70 
There  are  various  methods  to  calculate  the  prevalence  of  latent 
tuberculosis infection from this frequency distribution.71One method is based on 
mode-antimode technique. Here, when there is a clear cut antimode, touching the 
baseline, with two modes, the reactions are identified as those who make up the 
second mode after  the antimode.  This  method cannot  be applied to  our study 
because the antimode touches the baseline twice with a spurt in between. 
The  other  method  is  the  mirror-  image  technique.  In  this  method,  the 
highest frequency bar is identified from the second mode. The total number of 
reactors above this is taken (say X). This number is doubled (2X) to make up for 
both sides of the highest frequency (mirror  image).  This number (2X) is  then 
added to total number of subjects in the highest frequency (2x + y). This figure is 
divided by the total number of study subjects (=N) to get the prevalence of latent 
tuberculosis infection. Using this method the prevalence of latent TB infection is 
42%. 
According to RNTCP, latent tuberculosis is defined as indurations more 
than or equal to 10mm.72 As per the RNTCP definition; out of all 150 subjects, 
120 have an induration of ≥  10 mm i.e. 80%. This figure is high in comparison to 
other studies done in India.47, 48 Taking a cut-off of TST at ≥  5mm the prevalence 
of latent TB infection is 82% and if we take cut-off of  ≥ 15mm the prevalence 
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drops to 60%.From previous studies done in India as illustrated in table no.1, the 
prevalence of latent Tb infection in general population varies between 29.3% to 
65.0%. In studies  among contacts of sputum positive patients in India done by, 
Singh et al47 and Pai et al48 , the prevalence of latent TB varies between 41.3% to 
46.4%, as illustrated in table no.2.. This high prevalence (80%) can be explained 
by the fact that most of the index cases were taken from the “suspect MDR” cases 
and are likely to have been infective for a longer period.  So the contacts have 
higher chances of getting infection.  This is important as we need to know the 
prevalence of latent infection among contacts of suspected MDR cases as they 
have potential to develop primary MDR.
7.2 Prevalence of latent TB infection (LTBI) in adult and pediatric age.
Taking  a  TST  cut-off  of  10  mm  and  above,  the  prevalence  of  latent 
infection in the pediatric age group is 64%. In adult age group, the prevalence of 
latent TB infection, using a cut-off of 10mm and above is 88% as compared to 
just 65% prevalence obtained by QFT. In pediatric age the LTBI, using QFT is 
60% (Table 8). Using TST the LTBI in adult age is more than in pediatric and this 
difference  is  statistically  significant  (Table  No.  7).But  the  difference  in  LTBI 
among both the groups are not significantly different using QFT (Table No. 8)
This difference can be explained by the effect of cross reactivity of TST with 
other environmental mycobacteria, which is much more common in adults than in 
pediatric age. In case of pediatric age, which is less exposed to environmental 
mycobacteria than adults, the prevalence of latent TB infection using TST may be 
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due mainly to M. tuberculosis. This may be the reason why QFT also detects the 
same proportion of positive reactors in the pediatric age group. 
In  case  of  adults,  due  to  probable  exposure  to  environmental 
mycobacterium, which also renders TST to be falsely positive,  we get a large 
number of TST positives. In the same age group, the QFT positivity is only 65% 
showing that these positives may be those due to M.tuberculosis thus more or less 
negating the effect of many environmental mycobacteria. With increasing age, the 
proportion of people with TST positivity increases while the proportion of adults 
with QFT positive remains more or less the same(Table No.9; Figure No.2). This 
may also be due to the effect of environmental mycobacterium on TST. 
7.3 Difference in prevalence of LTBI  in  different groups
In relation to sex (Table No.10 & 11) there is no significant difference 
between male and female in both adult (in TST p value of 0.394 and in QFT p 
value of 0.153) and pediatric (in TST p value of 0.584 and in QFT p value of 
0.900).  This  shows  that  both  sexes  have  equal  chances  of  getting  latent 
infection from the infective case in the household.
In pediatric group, in both BCG vaccinated and unvaccinated individuals 
there is no significant difference in infection by TST (p value of 0.529) and 
QFT (p value of 0.797) as evident from table no. 12 & 13. The same is true in 
the case of adult population (p value with TST is 0.155 and 0.904 with QFT). 
This  indicates  that  the  prevalence  of  LTBI  is  not  influenced  by  BCG 
vaccination.
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Comparing the latent tuberculosis infection in adult group in relation to 
proximity of contact, it is observed that (Table No.14 & 15) contacts sleeping 
in the same room have a higher  chance of getting infection than contacts 
sleeping in different room(p value with TST is 0.012 and with QFT is 0.030). 
But in pediatric age group there is no statistically significant difference (p 
value with TST is 0.309 and with QFT is 0.297) between sleeping in same or 
different room. From the study it is evident that children are prone to develop 
LTBI if there is a household contact of infective TB, whether they share the 
same  room  or  not.  This  reinforces  the  stress  given  to  screen  household 
contacts in pediatric group of TB disease.72 
In case of adults who are educated up to primary class the LTBI is 
higher  than  those  who  are  more  educated,  but  this  difference  is  not 
statistically significant as illustrated in table no. 16 & 17. 
Adults who are home are more prone to infection than those who are 
working  outside.  This  may  be  due  to  longer  contact  in  those  staying  at 
home( Table 18 &19).
7.4 Comparison between TST and QFT
Many  studies  have  compared  the  agreement  between  whole  blood 
interferon gamma (QFT) assay with tuberculin skin test(TST) in low endemic 
countries.73 The agreement found in our study ( i.e., 84%) is consistent with the 
findings  from  majority  of  the  studies  in  the  endemic  countries.62,74,75,76(Table 
No.4).   In  one  study  by  Pai  et  al.  among  health  care  workers  in  India,  the 
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agreement between the two tests was found to be 81.4% which is consistent with 
our study findings.48 Another study in 2006 by Dogra et al. among hospitalized 
children in India have found an agreement  of 94% between interferon gamma 
assay and tuberculin skin test. 
With regard to BCG vaccination, previous studies have shown that there is 
a  positive  TST/  negative  IFN-γ  assay  discordance  in  those  who  are  BCG 
vaccinated. 75, 77 Our study showed that in BCG vaccinated individuals (Table No. 
21), the agreement is 90% whereas in BCG non- vaccinated individuals (Table 
No.22)  it  is  76%.  This  discrepancy may be  due  to  misclassification  of  BCG 
vaccine status owing to use of scar as a proxy.32 Recent tuberculin survey in India, 
involving more than 1 lakh children, have also shown that BCG vaccination does 
not  influence  the  estimation  of  annual  risk  of  infection.3 However,  BCG 
vaccination can have an effect on TST in other populations depending on vaccine 
strain, timing, frequency and time since vaccination.3 Another factor is the high 
prevalence of non-tubercular mycobacterium in India, which tends to cause non-
specific  sensitivity.3  Therefore,  non  tubercular  mycobacterium(NTM)  infection 
might have caused false-positive TST results. Because the QFT assays use RDI 
antigens,  the  effect  of  NTM on the  test  should be  limited.  However,  the  two 
proteins ( ESAT-6 and CFP-10) used in QFT have potential to cross react with 
some of the NTM species.59   It has been suggested that these proteins may cross 
react with  Mycobacterium leprae.78 Therefore, more studies are needed to study 
the effect of non- tubercular mycobacterium and M.leprae on IFN-γ  assays as 
these infections are endemic in India. 
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The TST is  highly sensitive and moderately specific,  depending on the 
population screened with specificity being more unpredictable. Several studies, 
have shown a positive association between TST response and subsequent risk of 
active  tuberculosis.8  Randomized  trials  have  shown  that  treatment  of  latent 
tuberculosis  infection,  diagnosed  using  TST,  reduces  the  risk  of  active 
tuberculosis by 60-90%.79  TST is simple test with less material cost although it 
requires skilled testers. 
In  contrast,  the  IFN-γ  assay(QFT)  have  higher  specificity  than  TST, 
limited cross reactivity due to non-tubercular mycobacterium infections, no cross-
reactivity due to BCG vaccinations and therefore better correlations with exposure 
to M. tuberculosis than TST.18,19,20 Few other advantages of QFT-G includes, only 
single visit by patient, elimination of subjective errors and no boosting effect.59 
But the most important drawback of QFT-G is the limited evidence of association 
of  QFT is  response  and  subsequent  progression  to  active  tuberculosis  among 
contacts of infective TB patients.57 No trials have demonstrated the efficacy of 
treatment based on IFN-γ  assay results. Another limitation of IFN-γ  assay is the 
need for laboratory infrastructure for the tests and its cost.
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8. SUMMARY
A cross sectional study was undertaken among the household contacts of sputum 
culture  positive  tuberculosis  patients  among suspected  MDR cases  in  Vellore, 
South India. Among a total of 147 suspected MDR cases who underwent sputum 
culture  testing,  104 were  found culture  positive.  Of  these  44  household  were 
contacted  and  40  household  agreed  to  participate  in  the  study.  In  these  44 
household , 154 household contacts were screened. Valid results were available 
for 150 individuals only. Of 150 for whom valid results are available, 120(80%), 
were found to be positive for latent tuberculosis infection by TST and 63.3% by 
QFT.  This  showed  a  high  prevalence  of  latent  tuberculosis  infection  among 
household contacts of infectious tuberculosis patients who are suspected to have 
MDR TB.  
The prevalence of latent tuberculosis infection among pediatric age group
( <15 years) , is 64% and in the adult age group is as high as 88%.This may be 
due to longer duration of contacts with infective case or due to exposure of adults 
to  environmental  mycobacterium.  Earlier  studies  have  shown  that  an  early 
detection  and  chemoprophylaxis  of  children  with  latent  tuberculosis  infection 
reduced the incidence of tuberculosis disease and is cost effective. This reinforced 
the  argument  that  we  need  to  focus  on  contact  tracing,  especially  among 
household contacts, to detect more number of latent tuberculosis infections. More 
studies need to be done to assess the prevalence of LTBI in contacts of special 
groups like MDR cases.
The study also showed a high agreement between TST and IFN-γ  assay in 
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detecting latent tuberculosis infection. The overall agreement between both the 
tests is 82% and kappa agreement of 0.571. This high agreement has also been 
reported by other studies both in endemic and non-endemic countries. 
This  result  has  shown that  both  the  tests  can  be  used  to  detect  latent 
tuberculosis infection. The decision to use any one of them will depend on the 
setting in which it is used and the resources available. In population, with low 
tuberculosis  infection,  where  cross-reactivity  with  other  environmental  non-
tubercular mycobacterium is an issue IFN-γ  assay can be used. IFN-γ  assay can 
also be used where serial  testing is  needed, as in special  groups as healthcare 
workers in contacts with tuberculosis patients. Furthermore, the IFN-γ  assay may 
be helpful in screening population in which low return rates for reading TST is a 
concern.
In high burden, resource limited countries like India, the TST might still 
serve a  useful  purpose.  In  India,  a  15-year  follow up of  2,80,000 individuals 
showed that TST response is significantly associated with development of active 
tuberculosis.8 In India, TST is widely used in diagnosing childhood tuberculosis 





1. A longer period of training for the readers and testers, as recommended by 
National Tuberculosis Institute, Bangalore, might have been more 
valuable.
2. Important covariates like infection with HIV or other non- tubercular 
mycobacterium infections were not measured.
3. This findings cannot be generalized on all sputum positive cases as the 
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11. ANNEXURE
1. Information Sheet: a. Tamil   b. English
2. Consent Form: a. Tamil b. English
3. Questionnaire-1
4. Questionnaire – 2
5. Drugs Controller General of India’s License to import and use 2TU -1
6. Drugs Controller General of India’s License to import and use 2TU -1
«õÖK½‹ Üî¡ ²ŸøˆF½‹, êOJ™ è£ê«ï£Œ A¼I è™êK™ õ÷˜„Cò¬ì‰î 
«ï£òOèÀì¡ i†®«ô£ Ü‚è‹ð‚èˆF«ô£ ªî£ì˜¹¬ìòõ˜èO¬ì«ò è£ê«ï£Œ Þ¼Šð¬î‚ è‡ìPò, 
è£ê«ï£Œ «î£™ ðK«ê£î¬ù ñŸÁ‹ °õ£¡®çªðó£¡ «è£œ† âùŠð´‹ ðK«ê£î¬ù 
ÜAòõŸP¡ Ýó£Œ„C. 
îèõ™ ð®õ‹
«ñ™ °PŠH†ì Ýó£Œ„CJ™ ðƒ°ªè£œ÷ î£ƒèœ Ü¬ö‚èŠð´Al˜èœ. Þ‰î Ýó£Œ„C 
ñ¼ˆ¶õ «ñ™ ð®ŠHŸè£è ªêŒòŠð´õî£°‹. Þ‰î Ýó£Œ„CJ¡ º‚Aò Ýó£Œ„Cò£÷˜ APˆ¶õ 
ñ¼ˆ¶õ‚ è™ÖKJ¡ êÍè ñ¼ˆ¶õ HK¬õ„ «ê˜‰î ñ¼. êˆFòTˆ ð†ï£ò‚ Ýõ£˜. Þ‰î 
Ýó£Œ„CJ™ î£ƒèœ ãø‚°¬øò 1 ñ£î‹ ðƒ°ªðø «õ‡® Þ¼‚°‹.
ÞîŸ° º¡ ïì‰î ðô Ýó£Œ„CèO™ êOJ™ è£ê«ï£Œ A¼I è™êK™ õ÷˜„Cò¬ì‰î 
«ï£òOèÀì¡ i†®«ô£ Ü‚è‹ð‚èˆF«ô£ ªî£ì˜¹¬ìòõ˜èO¬ì«ò è£ê«ï£Œ ãŸð´õîŸè£ù Üð£ò‹ 
ÜFèñ£è Þ¼‚Aø¶ â¡Á ªîKòõ‰¶œ÷¶. îŸ«ð£¶ Þˆî¬è«ò£Kì‹ è£ê «ï£¬ò‚ è‡ìPò 
àð«ò£èŠð´ˆîŠð´‹ ðK«ê£î¬ù ñ£¡«ì£ ðK«ê£î¬ù âùŠð´‹ è£ê «ï£Œ «î£™ 
ðK«ê£î¬ùò£°‹. °õ£¡®çªðó£¡ «è£œ† âùŠð´‹ ¹Fò Þóˆî ðK«ê£î¬ù»‹ Þõ˜èO¬ì«ò 
è£ê«ï£¬ò‚ è‡ìPò àî¾‹. 
î£ƒèœ/îƒèœ °ö‰¬î è£ê«ï£ò£O»ì¡ i†®«ô£ Ü‚è‹ð‚èˆF«ô£ ªî£ì˜¹¬ìòõó£è Þ¼‰î£™ 
Þ‰î Ýó£Œ„CJ™ ðƒ°ªðø î°Fò£ùõó£i˜. Þ‰î Ýó£Œ„CJ¡ ð°Fò£è îƒèOì‹ îƒèœ îQïð˜ 
Mõóƒèœ ñŸÁ‹ è£ê«ï£ò£O»ì¡ ªî£ì˜¹ ðŸPò Mõóƒèœ «è†ìPòŠð´‹. è£ê«ï£Œ «î£™ 
ðK«ê£î¬ù îƒèÀ‚° ªêŒòŠð´‹. «î£™ ðK«ê£î¬ùJ¡ Íô‹ «ï£Œ è‡ìPòŠ ð†ì£™ «ñ½‹ å¼ 
Þóˆî ðK«ê£î¬ù ªêŒòŠðìô£‹.  Ýó£Œ„C Fùˆî¡Á îƒèœ Þì¶ ¬èJ™ è£ê«ï£Œ «î£™ áC 
«ð£ìŠð´‹. Í¡Á ï£†èÀ‚°Š H¡ Ü‰î «î£™ áC ð®‚èŠð†´ îƒèÀ‚° º®¾ ÜPM‚èŠð´‹. îƒèÀ‚° 
è£ê «ï£Œ Þ¼Šð¶ è‡ìPòŠð†ì£™ îƒèOìI¼‰¶ 3 I™L Þóˆî‹ «êèK‚èŠðìô£‹. «ñ½‹ 
ê£† ñ¼ˆ¶õñ¬ùJ™ îƒèÀ‚° Üóê£ƒè º¬øŠð® «ñ½‹ ðK«ê£î¬ùèœ ñŸÁ‹ CA„¬ê 
ÜO‚èŠð´‹. Þ‰î Þó‡´ ðK«ê£î¬ùèÀ‹ Iè¾‹ ð£¶è£Šð£ù¬õ. è£ê«ï£Œ «î£™ 
ðK«ê£î¬ùJ¡«ð£¶ CP¶ «î£™ M¬÷¾èœ ãŸðìô£‹ Üù£™ Þ¬îˆîMø «õÁ M¬÷¾èœ 
â¶¾‹ Þ™¬ô. îƒèœ ðK«ê£î¬ù º®¾èœ ÞóèCòñ£è ¬õˆ¶‚ªè£œ÷Šð´‹, ò£¼‚°‹ 
ªîKM‚èŠðì£¶. Þ‰î Ýó£Œ„CJ™ î£ƒèœ ðƒ°ªè£œõ¶ º¿õ¶‹ ²òM¼ŠðˆFù£«ô«ò Ý°‹. 
âŠ«ð£¶ «õ‡´ñ£ù£½‹ î£ƒèœ ÜPMŠH™ô£ñ™ MôA‚ªè£œ÷ô£‹. 






ANNEXURE 1 b INFORMATION SHEET (ENGLISH)
Prevalence of latent tuberculosis infection among contacts of sputum culture 
positive tuberculosis patients in and around Vellore, using whole blood interferon 
gamma and tuberculin skin test. 
Information Sheet
You are invited to participate in the above mentioned study. This is a research project 
done towards the completion of a MD thesis. The principal investigator of the study is Dr. 
Satyajit Pattnaik, of the department of Community Medicine, Christian Medical College, 
Vellore. The duration of your participation in the study will be roughly about 1 month. 
In several studies it has been shown that people who are household or neighborhood 
contacts of patients whose sputum has grown the tuberculosis bacteria, are at high risk for 
tuberculosis disease. At present the Mantoux test (tuberculosis skin test) is the test used 
for screening for tuberculosis infection among contacts. Another new test, Quantiferon 
gold – a blood test, is also available for this purpose. 
If you/your child is/are a household or neighborhood contact of a patient whose sputum 
has grown tuberculosis bacteria, then you/your child will be eligible to participate in the 
study. As a part of the study, some basic questions will be asked about your personal 
information and contact history with the tuberculosis patient. You will have to undergo a 
skin test which will detect whether you have tuberculosis infection or not.  On the day of 
the study an injection will be placed on the left forearm. The study team will return after 
3 days to read the skin test. The reports will be notified to you. You may have to give 3ml 
blood for another test subsequent to the result of first test. In case you are detected to 
have tuberculosis infection, you will be offered further evaluation and treatment at 
CHAD hospital as per the government tuberculosis protocol. Both these tests have been 
proven to be safe and except mild reaction for the tuberculosis skin test, there are no 
foreseeable risks. The results of your/your child’s test will be kept confidential and will 
not be revealed to anybody. The participation in this study is purely voluntary and you 
may withdraw from the study at any point without any notification. 
If you have any further doubts or clarifications you may contact the principal investigator 
at the following address:
Dr. Satyajit Pattnaik
Community Health Department,
Christian Medical College, Bagayam
Phone – 0416-2284207
Mobile – 9944876043
ANNEXURE 2 a CONSENT FORM (TAMIL)
åŠ¹î™ ð®õ‹
Ýó£Œ„CJ¡ ªðò˜ -«õÖK½‹ Üî¡ ²ŸøˆF½‹, êOJ™ è£ê«ï£Œ A¼I è™êK™ õ÷˜„Cò¬ì‰î 
«ï£òOèÀì¡ i†®«ô£ Ü‚è‹ð‚èˆF«ô£ ªî£ì˜¹¬ìòõ˜èO¬ì«ò è£ê«ï£Œ Þ¼Šð¬î‚ è‡ìPò, 
è£ê«ï£Œ «î£™ ðK«ê£î¬ù ñŸÁ‹ °õ£¡®çªðó£¡ «è£œ† âùŠð´‹ ðK«ê£î¬ù 
ÜAòõŸP¡ Ýó£Œ„C. 
ðƒ°ªðÁðõ˜ ªðò˜ ___________________________________
õò¶ __________________ Hø‰îï£œ _____________________________
(1) Þ‰î îèõ™ ð®õˆ¬î ð®ˆ¶ ÞF™ Þ¼‚°‹ Mõóƒè¬÷Š ¹K‰¶ªè£‡«ì¡. âù‚° «èœMèœ 
«è†‚è õ£ŒŠðO‚èŠð†ì¶. 
(2) Þ‰î Ýó£Œ„CJ™, ï£¡/â¡ °ö‰¬î ðƒ° ªðÁõ¶ ²òM¼ŠðˆF¡ «ðK«ô«ò â¡Á ÜPA«ø¡. 
è£óí‹ â¶¾‹ Ãø£ñ™ âŠªð£¶ ªõ‡´ñ£ù£½‹ MôA‚ªè£œ÷ âù‚° àP¬ñ à‡´ â¡Á ÜPA«ø¡. 
(3) â¡/â¡ °ö‰¬îJì‹ «êèK‚èŠð´‹ Mõóƒèœ Ýó£Œ„Cò£÷˜èœ âŠ«ð£¶«õ‡´ñ£ù£½‹ 
àð«ò£èŠð´ˆF‚ªè£œ÷ ï£¡ ê‹ñF‚A«ø¡. ï£¡ Ýó£Œ„CJL¼‰¶ MôA‚ ªè£‡ì£½‹ Üõ˜èœ Ü
‰î Mõóƒè¬÷Š ðò¡ð´ˆF‚ªè£œ÷ ï£¡ ê‹ñF‚A«ø¡. Ýù£™ â¡/â¡ °ö‰¬îJ¡ îQïð˜ 
Ü¬ìò£÷ƒèœ ÞóèCòñ£è ¬õˆ¶‚ªè£œ÷Šð´‹ â¡Á ÜPA«ø¡. 
(4) Þ‰î Ýó£Œ„CJ™ ªîP»‹ MõóƒèO¡ M…ë£ùŠÌ˜õñ£ù àð«ò£èˆFŸ° ï£¡ ê‹ñî‹ 
ÜO‚A«ø¡. 
(5) «ñŸ°PŠH†ì Ýó£Œ„CJ™ ï£¡/â¡ °ö‰¬î ðƒ°ªðø ï£¡ ê‹ñF‚A«ø¡.









ANNEXURE 2 b CONSENT FORM (ENGLISH)
Study Title: Prevalence of latent tuberculosis infection among contacts of sputum 
culture positive tuberculosis patients in and around Vellore, using whole blood 
interferon gamma and tuberculin skin test. 
Subject’s Initials: _________ Subject’s Name: ________
Date of Birth / Age:_______
 (i)  I  confirm  that  I  have  read  and  understood  the  information  sheet  dated 
_________ for the above study and have had the opportunity to ask questions. [ ]
(ii) I understand that my participation in the study is voluntary and that I am
free to withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. [ ]
 (iii)  I  understand  that  the  principal  investigator,  others  working  on  the 
investigator’s behalf, the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I  
withdraw from the trial. I agree to this access. However, I understand that my 
identity  will  not  be  revealed  in  any  information  released  to  third  parties  or 
published. [ ]
(iv) I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s) [ ]
(v) I agree to take part in the above study. [ ]




Signature of the Investigator: ________________________
Date: _____/_____/______
Study Investigator’s Name: _________________________
Signature of the Witness: ___________________________
Date:_____/_____/_______
Name of the Witness: ______________________________
ANNEXURE 3 QUESTIONAIRE 1
TST – QFT   STUDY 2009
CHAD, CMC VELLORE, TAMIL NADU.  INDIA
Index Case No.
Contact Case No.
Name of Contact Age:                Sex:




Any symptoms of Tuberculosis (List all symptoms) :
Sleeping (in relation with Index Case): Same room / Same House but different room /
     Different House
Average number of hours spent with Index Case (per Day) :
ANNEXURE 4 QUESTIONAIRE 2
TST – QFT   STUDY 2009
CHAD, CMC VELLORE, TAMIL NADU.  INDIA
Index Case No.
Contact Case No.
Name of Contact Age:                Sex:




Any symptoms of Tuberculosis (List all symptoms) :
Sleeping (in relation with Index Case): Same room / Same House but different room /
     Different House
Average number of hours spent with Index Case (per Day) :





